- iCAD Inc ICAD reported Q2 adjusted EPS loss of $(0.11) slightly better than $(0.12) a year ago, but missing the consensus of $(0.07).
- Sales increased 41% Y/Y to $7.8 million, missing the wall street estimate of $9.15 million.
- "Our second-quarter total revenue was negatively impacted by longer than expected Enterprise sales cycles in several large prospective accounts. We began to close some of these accounts in July," said Mike Klein, Chairman and CEO.
- Cancer Detection revenue increased 16% Y/Y to $4.8 million
- Therapy revenue increased 109% to $3.0 million, primarily driven by the surge in dermatology controller installations reflecting positive shifts in market dynamics.
- The gross margin declined from 78% to 71%.
- Price Action: ICAD shares are down 29.2% at $10.90 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
